With docetaxel as effective chemotherapy for hormone refractory prostate cancer (HRPC), the number of new treatment combinations for HRPC is expanding demanding a fast-track screening system. This review elaborates on the use of xenograft models to select the most promising combination therapies for entering into phase II clinical trials.

, , ,
doi.org/10.1038/sj.bjc.6604822, hdl.handle.net/1765/27068
British Journal of Cancer
Erasmus MC: University Medical Center Rotterdam

van Weerden, W.M, Bangma, C.H, & de Wit, R. (2009). Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. British Journal of Cancer, 100(1), 13–18. doi:10.1038/sj.bjc.6604822